Sunil Samnani, Rishad Khan, Steven J. Heitman, Robert J. Hilsden, Michael F. Byrne, Samir C. Grover & Nauzer Forbes

Screening-related colonoscopy is a vital component of screening initiatives to both diagnose and prevent colorectal cancer (CRC), with prevention being reliant upon early and accurate detection of pre-malignant lesions. Several strategies, techniques, and interventions exist to optimize endoscopists’ adenoma detection rates (ADR).

“Hot off the press” paper on ways to improve adenoma detection in colonoscopy. I contributed the AI section. Thanks to senior author, Nauzer Forbes, and co-authors, Sunil Samnani, Rishad Khan, Steven Heitman, Robert Hilsden, and Samir C. Grover.

Dr. Michael Byrne
CEO & Founder
Satisfai Health 

Optimizing adenoma detection in screening-related colonoscopy

Date:  Published Online 10 May 2023


Artificial intelligence represents a new era within the field of gastroenterology, and the amount of research surrounding artificial intelligence in patients with inflammatory bowel disease is on the rise. 

Satisfai Health CEO & Founder Dr. Michael Byrne shares, “Further to our recent paper on AI in Clinical Trials for IBD, another review from our group has just been published on how Artificial Intelligence solutions are coming for the management of Inflammatory Bowel Disease in Clinical Practice and Future Directions.”

The purpose of this review is to provide an overview of the unmet needs in the management of inflammatory bowel disease in clinical practice and how artificial intelligence tools can address these gaps to transform patient care.

Artificial intelligence in inflammatory bowel disease

Date:  Published Online 20 April 2023

Satisfai Health sponsored and Satisfai Health CEO and Founder Dr. Michael Byrne, VP, Medical Affairs Dr. Nasim Parsa, and VP Business Development Ben Brzezynski participated in “The Future of Innovation in Esophageal Diseases”: From GERD to Esophageal Cancer event at DDW 2023.  Hosted by Northwestern Medicine Division of Gastroenterology and Esophageal Cancer Awareness Network (ECAN), the event assembled physician and industry experts and stakeholders to discuss the current state of innovation in esophageal diseases and gaps that need to be addressed in Innovation Thinktank panel discussions. 

“Having the who’s who from academia and industry in one room created great collaborative opportunities for this very important disease state. We strongly believe that Artificial Intelligence will play a key role in improving the management of Esophageal Cancer. Congratulations to Mindy Mintz Mordecai and Sri Komanduri for putting this incredible event together.” – Dr Michael Byrne 



Future of Innovation in Esophageal Diseases

Date: May 6 2023

Satisfai Health Scientific Advisor & Director of Upper GI Cancers Helmut Messmann and Advisor Jason Samarasena MD presented AI in BE Neoplasia Detection: The New Normal or Panacea at a Breakfast Connections session on May 7, 2023  at DDW 2023.

“Excellent Barretts AI session with experts, Helmut Messmann & Jason Samarasena presenting our latest AI models with real time expert level performance for detection, delineation & differentiation of dysplastic Barrett’s & early esophageal cancer.”  – Nasim Parsa, VP Medical Affairs.

Date: May 7, 2023

Satisfai Health  VP of Medical Affairs Nasim Parsa MD, co-moderated ASGE Meeting “The Environmental Challenges of Endoscopy” with Lyndon V Hernandez on May 8, 2023 at Disease Week® (DDW) in Chicago.

Nasim reports, “AI can help reduce the carbon footprint in GI endoscopy. It was great sharing the podium with Heiko Pohl, David Armstrong, Adam Silvka, Bu’Hussain Hayee, & Swapna Gayam.”



Date: May 8, 2023

Satisfai Health VP medical affairs Dr. Nasim Parsa presented the novel applications of CADx to arbitrate between discordant endoscopic & pathologic diagnosis in a World Endoscopy Organization (WEO) plenary meeting with session chairs Roupen Djinbachian and Daniel von Renteln  at DDW 2023 in Chicago. 

Nisam noted, “Endoscopist+CADx beats pathology’s accuracy for diminutive polyps in most scenarios”.


VP medical affairs Dr. Nasim Parsa presents on the novel applications of CADx DDW 2023

Date: May 5, 2023

Satisfai Health Chairman & CEO Dr. Michael Byrne, CFO & Director Murray Flanigan, VP of Medical Affairs Nasim Parsa MD, Chief Strategy Officer Solveig Johannessen, and VP of Business Development Ben Brzezinski  attended Digestive Disease Week® (DDW) in Chicago from May 6-9, 2023.

With 10,000 physicians, researchers and academics in attendance, DDW is the world’s premier meeting in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.


DDW 2023 Group Photo

Date: May 6 – 9,22, 2023

Vancouver, British Columbia, Canada, May 3, 2023– Satisfai Health Inc. (Satisfai), a leading medical company providing artificial intelligence solutions in the field of Gastroenterology, announces the addition of Ms. Solveig Johannessen as Chief Strategy Officer and Mr. Ben Brzezynski as Vice President of Business Development.

Ms. Johannessen and Mr. Brzezynski will focus on the Company’s mission to become the leading global provider of AI-powered clinical decision support and precision medicine solutions in Gastroenterology, GI Endoscopy, and Intestinal Ultrasound.

Ms. Johannessen is an accomplished leader with over two decades of experience designing and delivering innovative products, services, and customer experiences. As the Chief Strategy Officer at Satisfai, Solveig is responsible for developing and executing the Satisfai strategic plans to drive growth and profitability, while also leading efforts to innovate and transform the business.

Mr. Brzezynski is an experienced business development professional in the software, medical AI, and digital health fields. As VP of Business Development at Satisfai, Ben will lead market development and commercial strategy for Satisfai’s clinical products and contract research and development services.

“With the addition of Solveig and Ben to our leadership team, we will innovate and evolve many aspects of our product and services roadmap and strategy, while driving growth and profitability,” said Dr. Michael Byrne, Chairman & CEO of Satisfai Health.

Ms. Johannessen previously held a leadership role in Customer Strategy & Applied Design at Deloitte Digital and founded a successful Vancouver-based consultancy focused on business transformation, product strategy and experience design for clients including Molecular You, Light AI, Microbiome Insights, Avnet, CHC Helicopter, Heli-One, Contextual Genomics, The Personalized Medicine Initiative, and Pacific Autism Family Centre. She also has extensive experience in aviation and energy R&D, where she developed and delivered multi-faceted customer experiences and service innovation.

Mr. Brzezynski led global business development for ThinkSono and Enlitic, and previously worked as a lead medical services agreement negotiator for the British Columbia Medical Association. He designed and led successful commercial initiatives for computer vision and natural language processing technologies in the medical imaging, medical procedure guidance and telemedicine fields. He has delivered innovative technologies to market in the United States, Canada, Japan, the United Kingdom, Turkey, and the UAE, where he worked with physicians ranging from general practitioners to subspecialists and medical informaticians.

About Satisfai Health

Satisfai is a leading medical solutions provider specializing in AI applications applied to large addressable markets in gastroenterology. Satisfai’s solutions deliver real-time medical image analysis, providing clinicians with decision support intelligence that dramatically improves patient outcomes. Satisfai is supported by a highly respected board of clinicians and key opinion leaders who operate at the top of their fields in the many focus areas within gastroenterology. Satisfai enjoys a strong voice on academic panels and leading GI societies, and direct access to prominent industry players seeking to adopt new AI technologies in gastroenterology. For more information, visit

Satisfai Health Contact:

Mr. Andrew Stibbs


[email protected] 


In this review, state-of-the-art endoscopic assessment of mucosal disease activity in inflammatory bowel disease clinical trials is described, covering the potential for artificial intelligence to transform the current paradigm, its limitations, and suggested next steps.

“Artificial Intelligence solutions will change how clinical trials are conducted….for the better! Our review in Journal of Crohn’s and Colitis, jjad029 describes this opportunity in the field of inflammatory bowel disease.”

Dr. Michael Byrne
CEO &Founder
SatisFai Health

Artificial Intelligence in Inflammatory Bowel Disease Endoscopy

Date:  Published, 22 February 2023

Women in Gastroenterology & Hepatology Showcase Nasim Parsa MD, VP of Medical Affairs at Satisfai Health, will present “Artificial Intelligence in Clinical Medicine: A True Change or a Trend!” on September 22, 2023 at the Mayo Clinic Women in Gastroenterology & Hepatology Showcase. Her presentation is part of the AI session “Artificial Intelligence (AI) and My Future Practice: The Crystal Ball Ultimate Guide”. The event is a digital symposium delivered entirely by women of national and international recognition in the fields of gastroenterology and hepatology.

Date: September 22, 2023, Virtual


Request a Demo

Dr. Reno Panaccione

Director of IBD

Dr. Panaccione is currently a Professor of Medicine, the Director of the Inflammatory Bowel Disease Clinic at the University of Calgary and Director of Gastroenterology Research.

Dr. Panaccione graduated from the University of Western Ontario (London, Ontario) with a degree in Medicine in 1993. He went on to complete his Internal Medicine and Gastroenterology training at the University of Western Ontario and is certified as a fellow of the Royal College of Physicians and Surgeons of Canada in both Internal Medicine and Gastroenterology. Dr. Panaccione completed advanced training in Inflammatory Bowel Disease at the Mayo Clinic in Rochester, Minnesota. He joined the faculty of Medicine at the University of Calgary in 1999. He is an internationally recognized expert in inflammatory bowel disease. He has lectured nationally and internationally on various topics in inflammatory bowel disease and has delivered over 200 lectures in the last five years.

He is the author of many peer-reviewed articles (~250) and book chapters (25) on inflammatory bowel disease. His special interest lies in the fields of advanced therapies, biological therapy, and delivery of care through the implementation of clinical trials. He is a recognized authority on the use of biologics and has co-authored numerous guidelines on the management of inflammatory bowel disease for the Canadian Association of Gastroenterology. He actively participates in clinical trials of new therapeutic agents in Crohn’s disease and ulcerative colitis. He has published in and reviews for prestigious journals including NEJM, Lancet, Gastroenterology and Gut. He sits on the editorial board of Inflammatory Bowel Diseases, JCC, APT, and the Canadian Journal of Gastroenterology.

He is presently the medical director for the Crohn’s and Colitis Canada (CCC) Calgary Chapter and sits on the Medical Advisory council for the Crohn’s and Colitis Foundation of Canada. He is the national chair of the CCC scholarship program. He has been awarded the highest honour, the Finkelstein award by Crohn’s and Colitis Canada for his work in the field of IBD. He is also an elected member of the International Organization of Inflammatory Bowel Disease (IOIBD) reflecting his status in the area. He was awarded the CAG Visiting Professor Award in 2016 for his contribution o the field of Gastroenterology in Canada. He is ranked amongst the top ten experts in the field worldwide ( He presently holds a senior leadership position within Alberta Health Services as the Medical Lead for Systems Integration with the mandate of improving the efficiency and quality of care that is delivered to patients.

Dr. Douglas Rex

Director of Colorectal Cancer

Dr. Douglas K. Rex is Distinguished Professor of Medicine at Indiana University School of Medicine, Chancellor’s Professor at Indiana University Purdue University Indianapolis, and Director of Endoscopy at Indiana University Hospital in Indianapolis. He graduated from Harvard College, Summa Cum Laude in 1976 and with highest distinction from Indiana University School of Medicine in 1980. He served as Chief Medical Resident at Indiana University Hospital and joined the faculty at Indiana University in 1985. He received the Outstanding Teacher Award in the Introduction to Medicine course five times and has been awarded the Indiana University School of Medicine Outstanding Teacher Award as well as Department of Medicine’s Excellence in Teaching Award. He is a full-time clinical gastroenterologist at Indiana University Hospital.

His major research interests have been in colorectal disease and, in particular, colorectal cancer screening and the technical performance of colonoscopy. He co-authored the colorectal cancer screening recommendations of the American College of Gastroenterology and the U.S. Multi-Society Task Force on Colorectal Cancer. He also authored the recommendations on quality in colonoscopy of the U.S. Multi-Society Task Force on Colorectal Cancer and the American College of Gastroenterology/American Society of Gastrointestinal Endoscopy. He has authored more than 200 original research papers, 55 book chapters, 200 invited papers, 40 editorials, and 40 guideline papers. He is an Associate Editor of Journal Watch Gastroenterology and serves on the editorial boards of 11 gastroenterology journals.

He is the current chair of the U.S. Multi-Society (ACG, ASGE, AGA, ACP-ASIM) Task Force on Colorectal Cancer. He has also served in the American College of Gastroenterology as Chairman of the Board of Governors and is a Past President of the ACG. He is a member of the Governing Board of ASGE and a recipient of the Rudolph V. Schindler Award from ASGE.

Dr. Michael Byrne

CEO & Founder

Dr. Michael Byrne provides senior leadership and clinical expertise to Satisfai Health and is a clinical innovator with over 20 years experience as a practicing physician. He is the founder of both Satisfai Health and its ai4gi joint venture. He is a Clinical Professor of Medicine in the Division of Gastroenterology at Vancouver General Hospital and UBC. He is also director of the Interventional Endoscopy Fellowship at VGH, and is the former Director of Endoscopy at VGH/UBC.

He has worked in the medical device space for several years. Prior to his role with Satisfai Health and his participation in the ai4gi project, he has worked with the Biotechnology Industry in several areas including colon cancer genetic testing, and novel applications of Photodynamic therapy for Gastrointestinal disease.

He is a graduate of Cambridge and Liverpool Universities. He has a strong research background in both basic science and clinical medicine with hands-on training in molecular sciene and pharmacology. He received an MD by thesis from the University of Cambridge for his work on Helicobacter Pylori and Cyclooxygenase. He also has a long track record of clinical research. Dr. Byrne has published extensively with over 90 peer reviewed publications and over 100 abstract presentations at National and International Meetings.

After several years working in the UK and Ireland, Dr. Byrne completed an Interventional Endoscopy Fellowship as well as working as an attending physician at Duke University Medical Center, North Carolina. He moved to his current role in Vancouver in 2003.

His main clinical interests are in the field of ERCP, interventional endoscopy, optical biopsy, colon cancer, pancreaticobiliary disease, and IBD.